WO1996020284A1 - Hydroxyproline-rich proteins and pharmaceutical and cosmetic formulations containing them - Google Patents
Hydroxyproline-rich proteins and pharmaceutical and cosmetic formulations containing them Download PDFInfo
- Publication number
- WO1996020284A1 WO1996020284A1 PCT/EP1995/005084 EP9505084W WO9620284A1 WO 1996020284 A1 WO1996020284 A1 WO 1996020284A1 EP 9505084 W EP9505084 W EP 9505084W WO 9620284 A1 WO9620284 A1 WO 9620284A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- glycoproteins
- hydroxyproline
- biloba
- cosmetic
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/645—Proteins of vegetable origin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9771—Ginkgophyta, e.g. Ginkgoaceae [Ginkgo family]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/006—Antidandruff preparations
Definitions
- the present invention relates to hydroxyproline- rich glycoproteins which can be obtained from vegetable sources, and to the pharmaceutical and cosmetic use thereof . More precisely, the invention relates to hydroxyproline-rich glycoproteins, which can be obtained by acid alcohol extraction from Taxus spp.. Gin ⁇ ko bilQba, LYCOPersic ⁇ m esculentum and Daucus carota cell cultures, having the following characteristics: - average molecular weight 20,000 Daltons with variability interval 12,000 to 38,000, determined by means of gel permeation and electrophoresis; solubility in acid aqueous solutions.
- glycoproteins of animal origin such as collagen and proteoglycans
- Some glycoproteins of animal origin are known to exert a beneficial action on the skin when applied topically as such or incorporated in suitable formulations.
- Collagen which is a glycoprotein rich in proline and hydroxyproline, is especially used as such or combined with other polypeptide bases in the treatment of wrinkles and other unaesthetic blemishes linked to poor skin hydration and elasticity.
- the animal origin of collage limits its use because of the risks of contamination from viruses and toxins. Though the compounds of vegetable origin do not involve these risks, so far their use in cosmetics has been quite limited: for examples, cosmetic formulations are known which contain raw extracts of such plants as Aloe or even entire minced vegetables such as avocado.
- Vegetable glycoproteins that are produced from vegetable cells in the proliferation stage and have a similar structure to animal collagen, are known.
- EP-A-0 533 4078 discloses the cosmetic use of extensines having an average molecular weight above 100,000 Daltons.
- the methods for the extraction of extensines described to date which involve the extraction of vegetable materials of various origin by means of aqueous saline solutions, followed by purification with strong acids such as trichloroacetic acid, do not allow to obtain suitable products for cosmetics, due to problems concerning solubility, stability, repeatability and consistency of their chemical-physical characteristics.
- glycoproteins obtainable according to the invention have hydrating, film-forming, toning and cicat ⁇ zant properties higher than those of collagen.
- the glycoproteins of this invention can therefore be employed in cosmetic or dermatologic formulations for the treatment of dry skin, psoriasis, ichtyosis, dandruff, keratosis, wrinkles, acne, eczema, inflammatory der atosis, ageing of the skin and all the other applications for which the use of animal collagen has been proposed.
- aqueous solutions of the glycoproteins of the invention remain stable without any polymerisation of the glycoproteins leading to the formation of insoluble products.
- the viscosity of these solutions is particularly high and not dependent on the concentrations; 0.1% concentrations surprisingly have the same film-forming and hydrating power equal as 1% collagen or 5% vegetable albumin solutions.
- the vegetable material to be extracted is obtained from fermenter cultures of T_j_uj_u_S spp.. Gin ⁇ ko biloba. Lycopersicum esculentum and Daucus carota cells.
- the use of cells from the species Taxus SPP.. Gin ⁇ ko biloba and Lycopersicum esculentum is particularly preferred.
- the cell culture techniques are conventional and include the suspension culture starting from callus cultures from various parts of the plants such as leaves, bark, roots, trunk or seeds, as described by Dobbs and Roberts, Experiments in Plant Tissue Culture, 2nd ed. Cambridge University Press, New York, 1985.
- the vegetable tissue of the callus following sterilisation and optional addition of antibacterials, is typically used for the inoculum of suitable liquid culture media as described in the above mentioned Manual by Dobbs and Roberts.
- a particularly suitable medium for this invention is the Murashige and Skoog medium.
- specific additives such as proline, reducing agents, ethylene or compounds capable of releasing ethylene such as Ethephon or L-aminocyclo- propanecarboxylic acid, may be suitable to increase productivity in the desired glycoproteins.
- naphthylacetic acid as the as auxin, 6- (V, ⁇ -d ⁇ methylam ⁇ no)-pu ⁇ ne as the cytokimn, vitamins and 3% saccharose as the carbon source is preferred.
- the addition of vitamin C may be suitable, depending on the material chosen, to prevent the final product from browning.
- the fermentation time may vary from 3 to 12 days and is preferably between 5 and 6 days.
- the culture medium is centrifuged and the cellular mass is extracted by means of alcohols, preferably ethanol, in the presence of diluted mineral acids, preferably hydrochloric or sulphuric acid.
- alcohols preferably ethanol
- mineral acids preferably hydrochloric or sulphuric acid.
- This procedure inactivates some enzymes that may jeopardise the stability of the glycoproteins of the invention, specifically of polyphenoloxidase and tyrosine oxidase which favour the polymerization of glycoproteins with the consequent formation of insoluble products.
- the alcohol extraction in the presence of mineral acids allows the complete extraction of basic glycoproteins and has proved to be extremely selective to this end.
- the resulting hydroalcoholic extracts are neutralised and then concentrated and heated to a temperature of 70'C to 100'C, preferably around 80'C, up to complete precipitation of the denatured proteins.
- the suspension is then clarified by concentration and the fluid is subjected to fractional ultrafiltration to remove high and low molecular weight substances. Ultrafiltration is performed by means of polysulphonic membranes having cut-off of 10,000 Daltons to 40,000 Daltons, such as Centricon R or Romicon R , whose fibres may be hollow or, alternatively, coiled.
- the resulting filtered product is electrodialysed to remove undesired substances such as salts and low molecular weight sugars.
- the resulting solution can be used as such in cosmetic or pharmaceutical preparations or it can be concentrated to a lower volume and then lyophilised or atomised.
- the analytical characterization of the products of the invention was carried out by gel permeation using a high-pressure liquid chromatograph consisting of a Waters pump unit and provided with a Ultrahydrogel Linear Waters R column battery 30 cm x 0.5 cm and Waters UV absorption detector, model 484.
- An aqueous solution containing 0.067 M monopotassium phosphate, 0.1 M NaCl and 6 x 10 ⁇ 4 M aN 3 was used as the eluent.
- glycoprotein samples to be analysed are dissolved in the same eluent solution (3 mg/10 ml) and scalar amounts of the substance as well as the reference substances selected as molecular weights between Cytochrome C (12,400 Daltons) and dextran blue (2,000,000 Daltons); alternatively or simultaneously the products or their intermediates can be determined by electrophoresis on 12.5% polyacrylamide gel and 4% stacking gel.
- the samples to be analysed are dissolved in a buffer containing SDS and 0.1% mercaptoethanol while depositing quantities between 100 mg and 300 mg.
- the migration is carried out at a constant current at 20 mA for 4 hours.
- a gauging curve is drawn with 5 standard weights (7kD, 14kD, 24kD, 54kD and 66kD).
- Weights of 22.5kD and 25kD are calculated from this gauging curve for the two main bands and weights of 31kD and 34kD are calculated for the less intense bands.
- the procedures described here allow mixtures of products with comparable molecular weights and comparable amino acid compositions to be obtained from the various cell explants starting from different plants.
- the results of the amino acid analysis of glycoproteins extracted from Ginkgo biloba cells are shown below as an example.
- the above data refer to the percentage of the total amount of amino acids present in the glycoprotein mixture.
- the sugars in the mixture are arabinose and galactose.
- the ratio of amino acids to sugars is on average 2:1 for the various products.
- the products according to the invention can be used both in the pharmaceutical and cosmetic fields.
- the product may be incorporated in gels or ointments or applied on medicated gauzes for specific treatment of burns or wounds.
- the product is usually subjected to sterilisation or sterile filtrations and lyophilised.
- the cosmetic and dermatologic preparations of the invention can be prepared according to traditional methods.
- administration forms include aqueous sprays, lotions, solutions, emulsions, gels, ointments and creams.
- the cosmetic and dermatologic preparations of the inventions can contain hydroxyproline-rich glycoproteins in weight percentages of about 0.01% to about 50%, preferably from 0.05% to 5%, as well as conventional excipients. Given the high stability of the glycoproteins of this invention, pharmaceutical and cosmetic preparations containing above 50% of soluble hydroxyproline-rich glycoproteins can be obtained.
- glycoproteins of the invention can be added to pharmaceutical and cosmetic preparations as such or microencapsulated so as to provide a long-term hydrating action.
- the microcapsules can be either hydrophilic or lipophilic.
- the preparations of the invention may include other active principles having complementary or useful activity for the desired aims.
- the resulting explants are transferred to a Petri dish in Murashige & Skoog medium containing 3% saccharose with the addition of Lynsmeyer & Skoog vitamins and hormones such as 2,4- dichlorophenoxyacetic acid and naphthylacetic acid.
- the products are incubated in the dark at 23"C for 20 days. At the end of this period, friable calli are obtained which grow easily and are moved in continuous rows by means of subcultures in the same conditions, as they can be used for propagation in a liquid medium.
- the filtered product is then ultrafiltered using a hollow-fibre membrane with cut-off 10,000 Dalton to remove non-glycoprotein, low-molecular weight substances.
- the filtrate is then subjected to dialysis and concentrated to 1% of solid residue. 1.5 litres of a slightly viscous product is obtained, which may be used as such in cosmetic formulations.
- the product contained 6 bands, 4 of which had molecular weights of 16,000, 22,000, 33,000 and 36,000 Daltons.
- Example 2 a cell mass from sterile buds of Lycopersicum esculentum is prepared in a 14-liter fermenter containing 10 litres of Murashige & Skoog medium added with naphthylacetic acid and 6 ( ,V-dimethylamino)-purine, Lynsmeyer & Skoog vitamins and 3% saccharose as a carbon source.
- the fermentation is carried on for 5 days at 23*C while stirring at 150 rpm m the presence of yeast extract at 0.05% concentration and with an approximately 70% concentration of dissolved oxygen.
- the broth is gathered and micro-filtered through a 0.2 ⁇ ceramic membrane to concentrate the cells.
- Example 4 Some isopropanol containing 0.5% hydrochloric acid is added to the cell paste thus obtained and the method described in Example 2 is applied to the extracts. 3.5 litres of a solution are obtained with 0.5% dry residue. The analysis of the lyophilised solutions gave a content of 10% proline and 31% hydroxyproline, respectively.
- Example 4
- Cosmetic formulation 100 g of O/W emulsion contain: SOLUTION OF THE EXAMPLE 2 OR 3 10.0 g Acetylated lanolin alcohol PEG-10 2.0 g Cetyl-stearyl alcohol 1.5 g
- Example 5 Cosmetic formulation 100 g of O/W emulsion contain:
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Cosmetics (AREA)
- Peptides Or Proteins (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (18)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU43468/96A AU692654B2 (en) | 1994-12-28 | 1995-12-21 | Hydroxyproline-rich proteins and pharmaceutical and cosmetic formulations containing them |
DK95942191T DK0800585T3 (en) | 1994-12-28 | 1995-12-21 | Hydroxyproline-rich proteins and pharmaceutical and cosmetic formulations containing them |
KR1019970704423A KR100280030B1 (en) | 1994-12-28 | 1995-12-21 | Hydroxyfurin-rich protein and pharmaceutical and cosmetic preparations containing it |
PL95321004A PL182055B1 (en) | 1994-12-28 | 1995-12-21 | Proteins rich with hydroxyprolin and pharmaceutic and cosmetic compositions containing them |
AT95942191T ATE200518T1 (en) | 1994-12-28 | 1995-12-21 | HYDROXYPROLINE RICH PROTEINS AND PHARMACEUTICAL AND COSMETIC PREPARATIONS CONTAINING THEM |
US08/849,866 US6072030A (en) | 1994-12-28 | 1995-12-21 | Hydroxyproline-rich proteins and pharmaceutical and cosmetic formulations containing them |
SK860-97A SK280572B6 (en) | 1994-12-28 | 1995-12-21 | Hydroxyproline-rich glycoproteins and pharmaceutical and cosmetic formulations containing them |
HU9800203A HU220456B1 (en) | 1994-12-28 | 1995-12-21 | Hydroxyproline-rich proteins and pharmaceutical and cosmetic formulations containing them |
CZ19972024A CZ295489B6 (en) | 1994-12-28 | 1995-12-21 | Hydroxyproline-rich glycoproteins and preparations containing thereof |
CA002208960A CA2208960C (en) | 1994-12-28 | 1995-12-21 | Hydroxyproline-rich proteins and pharmaceutical and cosmetic formulations containing them |
DE69520693T DE69520693T2 (en) | 1994-12-28 | 1995-12-21 | HYDROXYPROLIN RICH PROTEINS AND PHARMACEUTICAL AND COSMETIC PREPARATIONS CONTAINING THEM |
SI9520146A SI9520146B (en) | 1994-12-28 | 1995-12-21 | Hydroxyproline-rich proteins and pharmaceutical and cosmetic formulations containing them |
EP95942191A EP0800585B1 (en) | 1994-12-28 | 1995-12-21 | Hydroxyproline-rich proteins and pharmaceutical and cosmetic formulations containing them |
JP8520195A JP2997063B2 (en) | 1994-12-28 | 1995-12-21 | Hydroxyproline-rich proteins and pharmaceutical and cosmetic preparations containing them |
NO19972984A NO318552B1 (en) | 1994-12-28 | 1997-06-26 | Hydroxyproline-rich proteins and pharmaceutical and cosmetic formulations containing them |
FI972757A FI118156B (en) | 1994-12-28 | 1997-06-26 | Hydroxyproline rich proteins and pharmaceutical and cosmetic compositions containing them |
HK98102928A HK1003652A1 (en) | 1994-12-28 | 1998-04-08 | Hydroxyproline-rich proteins and pharmaceutical and cosmetic formulations containing them |
GR20010400692T GR3035842T3 (en) | 1994-12-28 | 2001-05-09 | Hydroxyproline-rich proteins and pharmaceutical and cosmetic formulations containing them |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI94A002663 | 1994-12-28 | ||
ITMI942663A IT1271342B (en) | 1994-12-28 | 1994-12-28 | PROTEINS RICH IN HYDROXYPROLIN AND PHARMACEUTICAL AND COSMETIC FORMULATIONS CONTAINING THEM |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996020284A1 true WO1996020284A1 (en) | 1996-07-04 |
Family
ID=11370095
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1995/005084 WO1996020284A1 (en) | 1994-12-28 | 1995-12-21 | Hydroxyproline-rich proteins and pharmaceutical and cosmetic formulations containing them |
Country Status (24)
Country | Link |
---|---|
US (1) | US6072030A (en) |
EP (1) | EP0800585B1 (en) |
JP (1) | JP2997063B2 (en) |
KR (1) | KR100280030B1 (en) |
CN (1) | CN1109106C (en) |
AT (1) | ATE200518T1 (en) |
AU (1) | AU692654B2 (en) |
CA (1) | CA2208960C (en) |
CZ (1) | CZ295489B6 (en) |
DE (1) | DE69520693T2 (en) |
DK (1) | DK0800585T3 (en) |
ES (1) | ES2155541T3 (en) |
FI (1) | FI118156B (en) |
GR (1) | GR3035842T3 (en) |
HK (1) | HK1003652A1 (en) |
HU (1) | HU220456B1 (en) |
IT (1) | IT1271342B (en) |
NO (1) | NO318552B1 (en) |
PL (1) | PL182055B1 (en) |
PT (1) | PT800585E (en) |
RU (1) | RU2163266C2 (en) |
SI (1) | SI9520146B (en) |
SK (1) | SK280572B6 (en) |
WO (1) | WO1996020284A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999052988A1 (en) * | 1998-04-09 | 1999-10-21 | Mars Uk Limited | Adhesives |
US6379714B1 (en) | 1995-04-14 | 2002-04-30 | Pharmaprint, Inc. | Pharmaceutical grade botanical drugs |
KR100432426B1 (en) * | 2001-07-11 | 2004-05-22 | 엔프라니 주식회사 | Method for preparing Taxus seed extract and Taxus seed oil, and cosmetic composition containing them |
KR100472171B1 (en) * | 2001-07-11 | 2005-03-07 | 엔프라니 주식회사 | Method for preparing taxus extract and cosmetic composition for antiaging skin containing taxus extract |
WO2010058272A3 (en) * | 2008-11-19 | 2010-07-15 | Yoffi Agshach Ltd. | Cosmetics extracts obtainable from apiceae vegetables and especially from carrot taproots |
WO2020007959A1 (en) | 2018-07-06 | 2020-01-09 | Croda Italiana S.P.A. | Method of production of a plant cell extract of hydroxyproline rich glycoproteins including extensins |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2879443B1 (en) * | 2004-12-21 | 2007-07-13 | Jean Noel Thorel | USE OF A COMPLEX NUTRIENT BASE IN THE COSMETIC DOMAIN, IN PARTICULAR CAPILLARY |
DE102008052520A1 (en) * | 2008-10-21 | 2010-04-22 | Cognis Ip Management Gmbh | Cosmetic and / or pharmaceutical preparations |
KR101107925B1 (en) | 2009-06-08 | 2012-01-25 | 주식회사 바이오에프디엔씨 | Skin Composition for External Application Containing Tomato Callus and Preparing the Same |
CN102008401A (en) * | 2010-11-22 | 2011-04-13 | 马南行 | Biological preparation for relaxing facial muscles and preparation method thereof |
CN102827054B (en) * | 2012-08-25 | 2014-11-12 | 河北农业大学 | Hapten of L-hydroxyproline, artificial antigen, monoclonal antibody, preparation method and application |
CN105777884A (en) * | 2016-04-19 | 2016-07-20 | 贵州大学 | Plant-disease-resistant related protein NHRGP and encoding gene and application thereof |
WO2020008117A1 (en) | 2018-07-06 | 2020-01-09 | Laboratoires De Biologie Vegetale Yves Rocher | Cosmetic use of hrgp (hydroxyproline-rich glycoproteins) from ajuga reptans cells to prevent and/or combat the effects of skin ageing |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0533408A2 (en) * | 1991-09-18 | 1993-03-24 | Revlon Consumer Products Corporation | Cosmetics and pharmaceuticals containing extensins |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5443855B1 (en) * | 1991-09-18 | 1998-02-10 | Revlon Consumer Prod Corp | Cosmetics and pharmaceuticals containing extensins and related methods |
-
1994
- 1994-12-28 IT ITMI942663A patent/IT1271342B/en active IP Right Grant
-
1995
- 1995-12-21 AU AU43468/96A patent/AU692654B2/en not_active Ceased
- 1995-12-21 SK SK860-97A patent/SK280572B6/en not_active IP Right Cessation
- 1995-12-21 HU HU9800203A patent/HU220456B1/en not_active IP Right Cessation
- 1995-12-21 ES ES95942191T patent/ES2155541T3/en not_active Expired - Lifetime
- 1995-12-21 CA CA002208960A patent/CA2208960C/en not_active Expired - Fee Related
- 1995-12-21 JP JP8520195A patent/JP2997063B2/en not_active Expired - Fee Related
- 1995-12-21 US US08/849,866 patent/US6072030A/en not_active Expired - Fee Related
- 1995-12-21 WO PCT/EP1995/005084 patent/WO1996020284A1/en active IP Right Grant
- 1995-12-21 RU RU97112906/13A patent/RU2163266C2/en not_active IP Right Cessation
- 1995-12-21 CZ CZ19972024A patent/CZ295489B6/en not_active IP Right Cessation
- 1995-12-21 EP EP95942191A patent/EP0800585B1/en not_active Expired - Lifetime
- 1995-12-21 SI SI9520146A patent/SI9520146B/en not_active IP Right Cessation
- 1995-12-21 PL PL95321004A patent/PL182055B1/en not_active IP Right Cessation
- 1995-12-21 KR KR1019970704423A patent/KR100280030B1/en not_active IP Right Cessation
- 1995-12-21 DK DK95942191T patent/DK0800585T3/en active
- 1995-12-21 CN CN95197140A patent/CN1109106C/en not_active Expired - Fee Related
- 1995-12-21 AT AT95942191T patent/ATE200518T1/en active
- 1995-12-21 DE DE69520693T patent/DE69520693T2/en not_active Expired - Lifetime
- 1995-12-21 PT PT95942191T patent/PT800585E/en unknown
-
1997
- 1997-06-26 NO NO19972984A patent/NO318552B1/en not_active IP Right Cessation
- 1997-06-26 FI FI972757A patent/FI118156B/en not_active IP Right Cessation
-
1998
- 1998-04-08 HK HK98102928A patent/HK1003652A1/en not_active IP Right Cessation
-
2001
- 2001-05-09 GR GR20010400692T patent/GR3035842T3/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0533408A2 (en) * | 1991-09-18 | 1993-03-24 | Revlon Consumer Products Corporation | Cosmetics and pharmaceuticals containing extensins |
Non-Patent Citations (1)
Title |
---|
JOEL P. STAFSTROM ET AL.: "A SECOND EXTENSIN-LIKE HYDROXYPROLINE-RICH GLYCOPROTEIN FROM CARROT CELL WALLS.", PLANT PHYSIOL., vol. 84, 1987, pages 820 - 825, XP000569867 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6379714B1 (en) | 1995-04-14 | 2002-04-30 | Pharmaprint, Inc. | Pharmaceutical grade botanical drugs |
WO1999052988A1 (en) * | 1998-04-09 | 1999-10-21 | Mars Uk Limited | Adhesives |
AU754998B2 (en) * | 1998-04-09 | 2002-11-28 | Bttg | Adhesives |
KR100432426B1 (en) * | 2001-07-11 | 2004-05-22 | 엔프라니 주식회사 | Method for preparing Taxus seed extract and Taxus seed oil, and cosmetic composition containing them |
KR100472171B1 (en) * | 2001-07-11 | 2005-03-07 | 엔프라니 주식회사 | Method for preparing taxus extract and cosmetic composition for antiaging skin containing taxus extract |
WO2010058272A3 (en) * | 2008-11-19 | 2010-07-15 | Yoffi Agshach Ltd. | Cosmetics extracts obtainable from apiceae vegetables and especially from carrot taproots |
WO2020007959A1 (en) | 2018-07-06 | 2020-01-09 | Croda Italiana S.P.A. | Method of production of a plant cell extract of hydroxyproline rich glycoproteins including extensins |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU692654B2 (en) | Hydroxyproline-rich proteins and pharmaceutical and cosmetic formulations containing them | |
US6500470B1 (en) | Use of at least one protein extract of the moringa genus plant seeds and corresponding cosmetic and/or pharmacological composition | |
KR20100135871A (en) | Active ingredient that stimulates the proliferation and/or activity of fibroblasts | |
US8076296B2 (en) | Cosmetic compositions | |
JP2020193198A (en) | Fermented extract of aerial parts of bitter orange | |
KR20070019120A (en) | Anti-Wrinkle Cosmetic Composition Comprising the Extract of Paeonia lactiflora as Active Ingredient | |
KR20110076797A (en) | Extract of the plant ravenala madagascariensis and use as cosmetic hydrating agent | |
KR102381273B1 (en) | Cosmetic composition with promoting collagen synthesis and shirinking skin-pores, and Manufacturing method thereof | |
KR102281606B1 (en) | A multifunctional cosmetic composition for elasticity, anti-wrinkle, inhibiting tyrosinase comprising peptide complex | |
CZ202497A3 (en) | A portable device for measuring the impedance spectrum of steels and a measuring method | |
JPH11171784A (en) | External preparation for skin | |
KR20040087644A (en) | Cosmetic Composition Comprising Pyrus communis L. Extract for Skin Whitening | |
JPH09315930A (en) | Cosmetic material for skin | |
KR102382002B1 (en) | A multifunctional cosmetic composition for elasticity, anti-wrinkle, inhibiting tyrosinase comprising peptide complex and natural ingredients | |
KR102237543B1 (en) | Method of Producing DNA Derived from Aloe Genus Plant, and Composition Containing DNA Derived from Aloe Genus Plant for Anti-Aging and Anti-Inflammation | |
KR102628089B1 (en) | Cosmetic composition containing exosomes derived from Centella asiatica stem cell culture medium as an active ingredient and having cell regeneration and skin elastic effects | |
JPH10182402A (en) | Agent for promoting synthesis of hyaluronic acid | |
JP6944606B1 (en) | Manufacturing method of cosmetic composition | |
JPH07173026A (en) | Cosmetic | |
CN107739401B (en) | Method for constructing microbial cells to express beautifying polypeptide | |
CN108084253A (en) | Rich hydroxyproline albumen and the medicinal and cosmetic composition containing this albumen | |
KR20220147192A (en) | Cosmetics for skin whitening or wrinkle improvement comprising chlorella protothecoides extracts and method for preparing the same | |
KR20230152972A (en) | Functional cosmetic composition containing EGF as an active ingredient | |
WO2023149795A1 (en) | Method for producing an entomological compound with a keratolytic effect | |
JP2002201121A (en) | Plum water for cosmetic use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 95197140.9 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 08849866 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2208960 Country of ref document: CA Ref document number: 2208960 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV1997-2024 Country of ref document: CZ Ref document number: 1019970704423 Country of ref document: KR Ref document number: 972757 Country of ref document: FI Ref document number: 86097 Country of ref document: SK |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995942191 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1995942191 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: PV1997-2024 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1019970704423 Country of ref document: KR |
|
WWR | Wipo information: refused in national office |
Ref document number: 1019970704423 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1995942191 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: PV1997-2024 Country of ref document: CZ |